**Core tip:**β-catenin signaling consists of several pathway cascades, such as those that are involved in pluripotent stem cell generation and cancer. Several genes, including *EPHA8*, *SS18*, *ICE1*, *PTCH1*, *MSH3* and *CARD11*, are mutated along with *CTNNB1*. The expression of the *CTNNB1*, *CDH1*, *MYC*, *LEF1* and *TCF7L2* genes, which are related to the *CTNNB1* network, is up-regulated in diffuse-type GC cells compared to MSCs. 3D complex structures for β-catenin (CTNB1_HUMAN) with LEF_MOUSE and TF7L2_HUMAN were found using the HOMCOS database. The EMT-related gene *CTNNB1* plays an important role in pluripotent stem cell signaling and cancer signaling.

INTRODUCTION
============

Changes in the phenotypes of cancer and stem cells are related to changes in gene expression and protein signaling. This study aims to reveal the β-catenin (*CTNNB1*) regulation in diffuse-type gastric cancer (GC) cells and mesenchymal stem cells (MSCs). Wnt/β-catenin signaling is necessary for epithelial-mesenchymal transitions (EMT)\[[@B1]\]. Stem cell division is strongly correlated with cancer risk, and this highlights the importance of molecular signaling in stem cells and cancer cells\[[@B2]\]. Epigenetics and stem cell functions are regulated by several exogenous stimuli, including cell-cell and cell-matrix interactions\[[@B3]\]. To ensure the safety of therapeutic stem cell applications in terms of stem cell modification, an understanding of the regulation of the stem cells and their niche is necessary\[[@B4]\]. In the case of bone metastasis, the tissue-specific stromal response for prostate cancer can be identified by a molecular signature for which a novel mechanism has been revealed in hematopoietic and prostate epithelial stem cell niches\[[@B5]\].

Cancer stem cell (CSC) maintenance requires hypoxia-inducible factor (HIF)-α transcription factors and the inhibitor of DNA binding 2 (ID2)\[[@B6]\]. The down-regulated expression of ID2 is associated with a poor prognosis in hepatocellular carcinoma\[[@B7]\].

Because the compendium of gene expression, chromosomal copy number and sequencing data from human cancer cell lines, which is called the Cancer Cell Line Encyclopedia (CCLE), has revealed that genomic data are capable of predicting anti-cancer drug sensitivity, molecular and network analyses should be carried out\[[@B8]\]. It has been reported that cadherin 1 (*CDH1*) is up-regulated in diffuse-type GC cells compared to MSCs\[[@B9]\]. However, *CDH2* was down-regulated in diffuse-type GC cells compared to MSCs; this provides a useful indicator - the ratio of *CDH2* to *CDH1* expression - to distinguish the mesenchymal and epithelial phenotypes of the cells\[[@B9]\]. It has been reported that catenin β 1 (*CTNNB1*) is mutated in hepatocellular carcinoma\[[@B10],[@B11]\]. To further elucidate the EMT phenotype and the molecules that are involved in β-catenin signaling in cancer, the *CTNNB1* network and the β-catenin binding partners have been investigated in this report using bioinformatics tools such as microarray analysis and databases.

MATERIALS AND METHODS
=====================

Gene expression analysis of MSCs and diffuse-type GC cells
----------------------------------------------------------

Gene expression in MSCs (*n* = 12) and diffuse-type GC cells (*n* = 5) was analyzed using Human Genome U133 Plus 2.0 microarrays, as previously described\[[@B9],[@B12]\]. In brief, total RNA was purified from the cells, biotinylated and hybridized to microarrays. The signal intensity of each gene transcript was analyzed and compared between MSCs and diffuse-type GC cells. The microarray data for MSCs and diffuse-type GC cells are available to the public in NCBI's Gene Expression Omnibus (GEO) database and are accessible *via* GEO Series accession number GSE7888 (https://[www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc](www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc)=GSE7888) and GSE42252 (https://[www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc](www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc)=GSE42252), respectively\[[@B9],[@B12]\].

Diffuse-type GC tissues
-----------------------

Diffuse-type GC tissues were originally provided by the National Cancer Center Hospital after obtaining written informed consent from each patient and approval by National Cancer Center Institutional Review Board. All cancer specimens were reviewed and classified histopathologically according to the Japanese Classification of Gastric Cancer. Tissue specimens were immediately frozen with liquid nitrogen after surgical extraction, and stored at -80 °C until microarray analysis\[[@B9],[@B13]\]. The existing data already available to the public were analyzed in the article.

Analysis of cancer genomics using cBioPortal
--------------------------------------------

The cancer genomics data analysis was performed relative to *CTNNB1* using the cBioPortal for Cancer Genomics (<http://www.cbioportal.org>)\[[@B14],[@B15]\]. The term "CTNNB1" was searched in the cBioPortal for Cancer Genomics database, and a cross-cancer alteration summary was obtained for *CTNNB1*. A study on stomach adenocarcinoma was further analyzed for enrichments\[[@B16]\]. Genes with mutations that were enriched in samples that contained altered *CTNNB1* were selected in the cBioPortal for cancer genomics for further study.

3D complex structures
---------------------

3D complex structures were searched in the HOMology modeling of COmplex Structure (HOMCOS) database (<http://homcos.pdbj.org>) using the search engine that was provided by the VaProS server (<http://pford.info/vapros>)\[[@B17]\]. The UniProtID "CTNB_HUMAN" was input as the query for the "searching contact molecule" field of the HOMCOS. Only close homologues (sequence identity \> 95%) were selected. The complex structures that were found were superimposed using the MATRAS program\[[@B18]\].

Statistical analysis
--------------------

The data were expressed as the mean ± SE. For the statistics, Student's *t* test was used. *P* \< 0.01 was considered as statistically significant.

RESULTS
=======

Expression of EMT-related genes in MSCs and diffuse-type GC cells
-----------------------------------------------------------------

The expression of EMT-related genes in MSCs and diffuse-type GC cells is shown in Figure [1](#F1){ref-type="fig"}. The genes for which probe sets included the "EMT" term in the Gene Ontology (GO) Biological Process field were selected as EMT-related genes. The average signal intensity for early-stage MSCs, late-stage MSCs, or GC cells was greater than 500. Panel A shows the results of a cluster analysis of 39 probe sets that were up-regulated in diffuse-type GC cells compared to early-stage MSCs (*n* = 6 in early-stage MSCs, *n* = 6 in late-stage MSCs, *n* = 5 in GC). Panel B shows the results of a cluster analysis of 46 probe sets that were down-regulated in diffuse-type GC cells compared to early-stage MSCs (*n* = 6 in early-stage MSCs, *n* = 6 in late-stage MSCs, *n* = 5 in GC). To evaluate *CTNNB1* expression in cancer and stem cells, the expression of the *CTNNB1* gene was compared in MSCs and diffuse-type GC cells, and the results indicate that *CTNNB1* is up-regulated in GC cells (Figure [2](#F2){ref-type="fig"}). One of the probe sets was up-regulated more than 8-fold over its expression level in MSCs, whereas the other probe sets showed no increases in expression in GC cells compared to MSCs.

![Expression of epithelial-mesenchymal transition-related genes in mesenchymal stem cells and diffuse-type gastric cancer cells. Cluster analysis of gene expression in mesenchymal stem cells (MSCs) and diffuse-type gastric cancer (GC) cells. A: The result of the cluster analysis of 39 probe sets that were up-regulated in diffuse-type GC cells compared to early-stage MSCs (*n* = 6 in early-stage MSCs, *n* = 6 in late-stage MSCs, *n* = 5 in GC); B: The result of the cluster analysis of 46 probe sets that were down-regulated in diffuse-type GC cells compared to early-stage MSCs (*n* = 6 in early-stage MSCs, *n* = 6 in late-stage MSCs, *n* = 5 in GC). The probe sets with epithelial to mesenchymal transition in the Gene Ontology Biological Process were selected (the average signal intensity in early-stage MSCs, late-stage MSCs, or GC cells is greater than 500).](WJSC-8-384-g001){#F1}

![*CTNNB1* expression in mesenchymal stem cells and diffuse-type gastric cancer cells. *CTNNB1* gene expression was up-regulated in GC cells compared to MSCs. The signal intensity of probe set ID 223679_at was up-regulated more than 8-fold in GC cells compared to MSCs, whereas the signal intensity in probe set ID 201533_at was unchanged (*n* = 12 in MSC, *n* = 5 in GC, ^a^*P* \< 0.01 in *t* test). GC: Gastric cancer; MSCs: Mesenchymal stem cells.](WJSC-8-384-g002){#F2}

3D complex structures of β-catenin
----------------------------------

To verify and explore protein-protein interactions with β-catenin, 3D complex structures of β-catenin were found using the HOMCOS database (<http://homcos.pdbj.org>)\[[@B17]\] and are summarized in Table [1](#T1){ref-type="table"}. Figure [3](#F3){ref-type="fig"} shows the superimposed 3D structure of the complex. Most of the proteins bind to the inner concave surface of the armadillo repeat region of β-catenin by using their 40-60 residue length extended peptides \[adenomatous polyposis coli protein (APC), E-cadherin 1 (CDH1), catenin beta interacting protein 1 (CTNNBIP1), lymphoid enhancer binding factor 1 (LEF1), transcription factor 7 like 1 (TCF7L1) and transcription factor 7 like 2 (TCF7L2)\]. CDH1 and B-cell CLL/lymphoma 9 (BCL9) bind to the N-terminal region of the repeat that has the alpha-helical peptides. The nuclear receptor subfamily 5 group A member 2 (NR5A2) ligand binding domain binds to the middle of the armadillo repeat region. Of these binding factors, the transcription of the *CDH1*, *LEF1* and *TCF7L2* genes was up-regulated in GC cells (Table [1](#T1){ref-type="table"}). It has been reported that a small molecule antagonist of the β-catenin/T-cell transcription factor 4 \[TCF4; official name is transcription factor 7 like 2 (TCF7L2)\] interaction inhibits self-renewal of CSCs and suppresses tumorigenesis\[[@B19]\]. The 3D complex structures of β-catenin and TCF7L2 are available\[[@B20],[@B21]\]. The complex structure of NR5A2 has also been reported\[[@B22]\]. NR5A2 (or liver receptor homolog-1; LRH1) is a member of the nuclear hormone receptor family of transcription factors that play essential roles in development, metabolism, and cancer and are implicated in Wnt/β-catenin signaling\[[@B22]\]. NR5A2 is essential for the early development and maintenance of pluripotent mouse embryonic stem (ES) cells\[[@B22],[@B23]\]. Network models for CTNNB1, the Wnt signaling pathway, Hippo signaling pathway and adherens junction signaling in cancer are shown in Figure [4](#F4){ref-type="fig"}. CTNNB1 binds to CDH1 near the cellular membrane or to TCF to transcribe anti-apoptotic or pro-proliferation genes, such as SRY-box 2 (*SOX2*) or v-myc avian myelocytomatosis viral oncogene homolog (*MYC*) (Figure [4](#F4){ref-type="fig"}). Wnt stimulation prevents glycogen synthase kinase 3 beta (GSK3β) from phosphorylating CTNNB1 and leads to CTNNB1 translocation into the nucleus to induce transcription. The 3D complex structure (PDB code: 1m1e) clearly shows how CDH1 binds to CTNNB1 in the mouse model.

###### 

3D complex structures of β-catenin (CTNNB1) and interacting proteins

  **pdb_id**   β**-catenin (CTNNB1)**   **Proteins that interact with β-catenin**                                                                                                    
  ------------ ------------------------ ------------------------------------------- ------------- ---------- --- ----- ------------- ----------------------------------------------- ---------------
  1th1         B                        513                                         CTNB1_HUMAN   APC        D   54    APC_HUMAN     Adenomatous polyposis coli protein              Not changed/-
  1qz7         A                        524                                         CTNB1_HUMAN   AXIN1      B   17    AXN_XENLA     Axin-1                                          \-
  3sl9         B                        165                                         CTNB1_HUMAN   BCL9       D   23    BCL9_HUMAN    B-cell CLL/lymphoma 9 protein                   \-
  1i7w         C                        509                                         CTNB1_MOUSE   CDH1       D   60    CADH1_MOUSE   Cadherin-1                                      Up-regulated
  1m1e         A                        512                                         CTNB1_MOUSE   CTNNBIP1   B   65    CNBP1_HUMAN   Beta-catenin-interacting protein 1              \-
  3oux         A                        503                                         CTNB1_MOUSE   LEF1       B   47    LEF1_MOUSE    Lymphoid enhancer-binding factor 1              Up-regulated
  3tx7         A                        504                                         CTNB1_HUMAN   NR5A2      B   218   NR5A2_HUMAN   Nuclear receptor subfamily 5 group A member 2   \-
  1g3j         A                        439                                         CTNB1_HUMAN   TCF7L1     B   34    T7L1A_XENLA   Transcription factor 7-like 1-A                 \-
  1jdh         A                        508                                         CTNB1_HUMAN   TCF7L2     B   38    TF7L2_HUMAN   Transcription factor 7-like 2                   Up-regulated
  1dow         B                        32                                          CTNB1_MOUSE   CTNNA1     A   205   CTNA1_MOUSE   Catenin alpha-1                                 Not changed/-
  4ons         D                        56                                          CTNB1_MOUSE   CTNNA2     C   230   CTNA2_MOUSE   Catenin alpha-2                                 \-

![3D structures of β-catenin (CTNNB1) binding proteins. Each CTNNB1 complex structure was superimposed onto the CTNNB1 structure in a complex with APC (PDB code: 1th1), using the program MATRAS (From Ref. \[18\]). Colors and PDB codes are summarized as follows: White: CTNNB1 (CTNB1_HUMAN, 1th1); red: APC (APC_HUMAN, 1th1); orange: AXIN1 (AXN_XELNA, 1qz7); hot pink: BCL9 (BCL9_HUMAN, 3sl9); green: CDH1 (CADH1_MOUSE. 1i7w); cyan: CTNNBIP1 (CNBP1_HUMAN, 1m1e); magenta: LEF1 (LEF1_MOUSE, 3oux); forest green: NR5A2 (NR5A2_HUMAN, 3tx7); yellow: TCF7L1 (T7L1A_XENLA, 1g3j); blue: TCF7L2 (TF7L2_HUMAN, 1jdh).](WJSC-8-384-g003){#F3}

![Network model for CTNNB1. The molecular network model for CTNNB1 signaling is shown. The extracted networks for pathways in cancer, Hippo signaling pathway and the Wnt signaling pathway (KEGG) were merged and are shown in a molecular network model. Wnt signaling and adherens junction molecules cross-talk *via* CTNNB1. Activated CTNNB1 induces the transcription of anti-apoptosis genes and pro-proliferation genes.](WJSC-8-384-g004){#F4}

CTNNB1 pathway (Kyoto Encyclopedia of Genes and Genomes)
--------------------------------------------------------

CTNNB1 is listed in 21 pathways in Kyoto Encyclopedia of Genes and Genomes (KEGG), including the Rap1 signaling pathway, Wnt signaling pathway, Hippo signaling pathway, focal adhesion regulation, adherens junction regulation, tight junction regulation, signaling pathways that regulate the pluripotency of stem cells, leukocyte transendothelial migration, melanogenesis, the thyroid hormone signaling pathway; bacterial invasion of epithelial cells, pathogenic *Escherichia coli* infection, HTLV-I infection, and various cancer pathways. The following conditions use the aforementioned pathways and are also thus implicated: Proteoglycans in cancer, colorectal cancer, endometrial cancer, prostate cancer, thyroid cancer, basal cell carcinoma, and arrhythmogenic right ventricular cardiomyopathy (ARVC) (<http://www.genome.jp/dbget-bin/www_bget?hsa>:1499). The inhibition of GSK3β kinase activates β-catenin, which stimulates endoderm induction *via* the degradation of Tcf7l1 and forkhead box A2 (FoxA2) expression\[[@B24]\]. Wnt signaling induces intracellular β-catenin signaling *via* GSK3β kinase inhibition and dephosphorylation of β-catenin\[[@B25]-[@B28]\]. The inhibition of β-catenin decreases proliferation and induces apoptosis in the mantle cell lymphoma cell line\[[@B29]\]. Noncanonical Wnt signaling is activated in circulating tumor cells from the prostate that are anti-androgen-resistant\[[@B30]\].

Mutations in CTNNB1 and related genes (cBioPortal: Stomach adenocarcinoma)
--------------------------------------------------------------------------

The Cancer Genome Atlas Research Network project has indicated that there is a characteristic molecular signature for ras homolog family member A (*RHOA*) mutations in diffuse type stomach adenocarcinoma\[[@B16]\]. Two-hundred and ninety-five primary gastric adenocarcinomas have been investigated, and mutations in *RHOA* have been enriched in genomically stable subtype, diffuse-type GC cells\[[@B16]\]. The analysis with cBioPortal showed that *CTNNB1* was altered in 24 (8%) of 287 cases/patients in stomach adenocarcinoma: 4 amplifications, 2 deep deletions, 12 missense mutations, 5 truncating mutations and 1 inframe mutation. Several gene mutations occurred concurrently with *CTNNB1* alterations in stomach adenocarcinoma (Table [2](#T2){ref-type="table"}). The development of mutations in EPH receptor A8 (*EPHA8*), synovial sarcoma translocation chromosome 18 (*SS18*), interactor of little elongator complex ELL subunit 1 (*ICE1*), patched 1 (*PTCH1*), mutS homolog 3 (*MSH3*) and caspase recruitment domain family member 11 (*CARD11*) occurred alongside the *CTNNB1* alterations (Table [2](#T2){ref-type="table"}). Of the mutated genes, *PTCH1* expression was up-regulated in GC cells compared to MSCs (Table [2](#T2){ref-type="table"}). The GO of the mutated genes is shown in Table [3](#T3){ref-type="table"}. EPHA8 possesses kinase activity, SS18 is involved in cell morphogenesis, ICE1 may play a role in positive regulation of intracellular protein transport, PTCH1 is involved in morphogenesis and cell growth, MSH3 is involved in mismatch repair, and CARD11 regulates B cell proliferation, apoptosis and NF-κB signaling, according to GO biological process (Table [3](#T3){ref-type="table"}). GO biological process terms in Table [3](#T3){ref-type="table"} are based on Affymetrix annotation (<http://www.affymetrix.com/estore/>) and gene information in NCBI (<http://www.ncbi.nlm.nih.gov/>).

###### 

Genes mutated along with the *CTNNB1* alteration

  **Gene symbol**   **Gene title**                                         **Cytoband**   **Mutation percentage**   **Log ratio**   ***P*-value**   **Ratio of GC cells to MSCs**   
  ----------------- ------------------------------------------------------ -------------- ------------------------- --------------- --------------- ------------------------------- -------------------------
  EPHA8             EPH receptor A8                                        1p36.12        29.17%                    2.28%           3.68            1.45E-05                        Signal intensity is low
  SS18              Synovial sarcoma translocation Chromosome 18           18q11.2        16.67%                    0.00%           \> 10           3.84E-05                        0.6
  1.4                                                                                                                                                                               
  ICE1              Interactor of little elongator complex ELL subunit 1   5p15.32        33.33%                    4.56%           2.87            4.74E-05                        1.5
  PTCH1             Patched 1                                              9q22.3         29.17%                    3.42%           3.09            8.16E-05                        16.6
  MSH3              MutS homolog 3                                         5q14.1         20.83%                    1.14%           4.19            1.28E-04                        Signal intensity is low
  CARD11            Caspase recruitment domain family, member 11           7p22           29.17%                    4.18%           2.8             2.03E-04                        Signal intensity is low

###### 

Gene ontology of mutated genes along with *CTNNB1* alteration

  **Gene symbol**   **Gene ontology biological process**
  ----------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  EPHA8             Protein phosphorylation // substrate-dependent cell migration // cell adhesion // transmembrane receptor protein tyrosine kinase signaling pathway // multicellular organismal development // nervous system development // axon guidance // phosphorylation // neuron remodeling // peptidyl-tyrosine phosphorylation // regulation of cell adhesion // neuron projection development // regulation of cell adhesion mediated by integrin // positive regulation of MAPK cascade // positive regulation of phosphatidylinositol 3-kinase activity // protein autophosphorylation // ephrin receptor signaling pathway
  SS18              Microtubule cytoskeleton organization // cell morphogenesis // transcription, DNA-templated // regulation of transcription, DNA-templated // cytoskeleton organization // response to drug // positive regulation of transcription from RNA polymerase II promoter // ephrin receptor signaling pathway
  ICE1              Positive regulation of intracellular protein transport // positive regulation of protein complex assembly // positive regulation of transcription from RNA polymerase III promoter // snRNA transcription from RNA polymerase II promoter // snRNA transcription from RNA polymerase III promoter
  PTCH1             Negative regulation of transcription from RNA polymerase II promoter // branching involved in ureteric bud morphogenesis // neural tube formation // neural tube closure // heart morphogenesis // signal transduction // smoothened signaling pathway // smoothened signaling pathway // regulation of mitotic cell cycle // pattern specification process // brain development // negative regulation of cell proliferation // epidermis development // regulation of smoothened signaling pathway // response to mechanical stimulus // organ morphogenesis // dorsal/ventral pattern formation // response to chlorate // positive regulation of cholesterol efflux // response to organic cyclic compound // protein processing // spinal cord motor neuron differentiation // neural tube patterning // dorsal/ventral neural tube patterning // neural plate axis specification // embryonic limb morphogenesis // mammary gland development // response to estradiol // response to retinoic acid // regulation of protein localization // limb morphogenesis // hindlimb morphogenesis // regulation of growth // negative regulation of multicellular organism growth // regulation of cell proliferation // response to drug // glucose homeostasis // negative regulation of sequence-specific DNA binding transcription factor activity // keratinocyte proliferation // negative regulation of osteoblast differentiation // negative regulation of smoothened signaling pathway // negative regulation of smoothened signaling pathway // negative regulation of epithelial cell proliferation // negative regulation of cell division // pharyngeal system development // mammary gland duct morphogenesis // mammary gland epithelial cell differentiation // smoothened signaling pathway involved in dorsal/ventral neural tube patterning // cell differentiation involved in kidney development // somite development // cellular response to cholesterol // cellular response to cholesterol // renal system development // cell proliferation involved in metanephros development // protein targeting to plasma membrane
  MSH3              Meiotic mismatch repair // ATP catabolic process // DNA repair // mismatch repair // cellular response to DNA damage stimulus // reciprocal meiotic recombination // somatic recombination of immunoglobulin gene segments // maintenance of DNA repeat elements // negative regulation of DNA recombination // positive regulation of helicase activity
  CARD11            Positive regulation of cytokine production // signal transduction // positive regulation of B cell proliferation // T cell costimulation // Fc-epsilon receptor signaling pathway // positive regulation of T cell proliferation // regulation of apoptotic process // positive regulation of I-kappaB kinase/NF-kappaB signaling // thymic T cell selection // positive regulation of interleukin-2 biosynthetic process // innate immune response // regulation of B cell differentiation // regulation of T cell differentiation // nucleotide phosphorylation // regulation of immune response // T cell receptor signaling pathway // positive regulation of T cell activation // positive regulation of NF-kappaB transcription factor activity

β-catenin signaling model
-------------------------

Several β-catenin-binding proteins, such as LEF1 or TCF7L2, share high mobility group (HMG)-box domains, which suggests that β-catenin signaling switches mechanisms with the binding of different transcription factors. 3D complex structures show that CDH1, LEF1 and TCF7L2 bind to β-catenin. The role of β-catenin signaling in the pluripotentcy pathway should be investigated to reveal its mechanism in cancer and stem cells. The Wnt pathway is located upstream, and TCF, downstream of CTNNB1 in the cascade\[[@B31]\]. The merged network model of the β-catenin signaling network and CDH1, together with molecules in the 3D complex structures and genes mutated along with the *CTNNB1* alteration is shown in Figure [5A](#F5){ref-type="fig"}. The merged network model of the *CTNNB1*, *Wnt*, and *TCF* signaling networks and *CDH1*, together with molecules in the 3D complex structures and genes mutated along with the *CTNNB1* alteration is shown in Figure [5B](#F5){ref-type="fig"}. Of the common genes, EPHA8, SS18 and PTCH1 interact with phosphatidylinositol-4,5-bisphosphate-3-kinase catalytic subunit gamma (PIK3CG), SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (SMARCA4), and GLI family zinc finger 1 (GLI1), respectively, whereas CARD11, ICE1, MSH3 have no known interactions with molecules in the CTNNB1 network. The networks for stomach adenocarcinoma that were generated using cBioPortal for Cancer Genomics for CTNNB1 alone and for CTNNB1 with the 6 genes that are mutated along with the *CTNNB1* alteration have been partially merged in Figure [5](#F5){ref-type="fig"}. Catenin delta 2 (*CTNND2*) and erb-b2 receptor tyrosine kinase 2 (*ERBB2*) showed a relatively high frequency of mutation (\> 15% in 287 tumor samples) in the analysis using cBioPortal for Cancer Genomics of the *CTNNB1* network in stomach adenocarcinoma (TCGA, Nature 2014)\[[@B16]\]. The genes that were up-regulated in GC cells compared to MSCs are shown in red, whereas the down-regulated genes are shown in light blue (Fold change \> 2, *P* \< 0.05, *n* = 12 in MSCs, *n* = 5 in GC; the average signal intensity of MSCs or GC cells is greater than 500). The expression of the *CTNNB1*, *CDH1*, notch1 (*NOTCH1*), hepatocyte growth factor (*HGF*), *PTCH1*, discs large homolog 1, scribble cell polarity complex component (*DLG1*), *LEF1*, *CTNND1*, *SMARCA4*, nuclear receptor coactivator 2 (*NCOA2*), SMAD family member 4 (*SMAD4*), *MYC*, junction plakoglobin (*JUP*), *TCF7L2* and *ERBB2* genes was up-regulated in GC cells compared to MSCs, whereas the expression of twist family bHLH transcription factor 1 (*TWIST1*) was down-regulated in GC cells compared to MSCs. The expression of *EPHA2* was up-regulated in some GC samples. The expression of the IQ motif-containing GTPase activating protein 1 (*IQGAP1*), *SS18*, *ICE1*, cortactin (*CTTN*), *RHOA*, CREB binding protein (*CREBBP*) and protein tyrosine phosphatase, non-receptor (*PTPN1*) genes was not altered in MSCs and GC cells. The expression of the *EPHA8*, *PIK3CG*, *CARD11*, *MSH3*, *GLI1*, epidermal growth factor receptor (*EGFR*), snail family zinc finger 1 (*SNAI1*) and *CTNND2* genes was not examined due to a low signal intensity. The alteration frequencies of *CTNND2* and *ERBB2* are relatively high in the CTNNB1 network (\> 15%), according to the cBioPortal for Cancer Genomics. Interestingly, *IQGAP2* was up-regulated in GC cells compared to MSCs.

![Network model for *CTNNB1* and related genes. A: Network model for *CTNNB1* and genes mutated along with *CTNNB1*. The networks of extracted *CTNNB1* with other mutated genes plus that of extracted *CTNNB1* alone are shown (cBioPortal-oriented, Stomach Adenocarcinoma)\[[@B16]\]; B: Network model for *CTNNB1* and 6 mutated genes. Wnt and LEF/TCF signaling are merged in *CTNNB1* signaling (cBioPortal-oriented, Stomach Adenocarcinoma)\[[@B16]\].](WJSC-8-384-g005){#F5}

DISCUSSION
==========

In summary, the *CTNNB1* gene expression was up-regulated in diffuse-type GC compared to MSC. The various molecules are regulated with *CTNNB1*, which suggests the *CTNNB1* signaling network in cancer and stem cells. EMT-related genes have been reported to be induced by transforming growth factor (TGF)-β or epidermal growth factor (EGF), and genes in the Wnt signaling pathway are mutated in non-small cell lung cancer\[[@B32]-[@B34]\]. The expression of β-catenin was up-regulated in the TGF-β1-induced EMT model and was inhibited by cucurbitacin B treatment\[[@B32]\]. Solid tumors induce hypoxia, leading to HIF-1α protein regulation of molecules that are involved in angiogenesis, erythropoiesis, metabolism, cell survival and cell proliferation\[[@B35]\]. *SNAI2* and *TWIST1* were down-regulated in GC cells compared to MSCs, whereas *SNAI1* expression was not detected because of low signal intensity\[[@B9],[@B36],[@B37]\]. Because SNAI and TWIST are associated with EMT, the regulation of their expression is important for understanding EMT mechanisms. Although 3D complex structures of SNAI2 and TWIST1 with β-catenin are not available, some indirect β-catenin signaling cascade may be involved in the SNAI2 and TWIST1 pathway\[[@B38],[@B39]\]. TGFβ is also an important factor in EMT\[[@B40]\]. TGFβ regulates osteoblast differentiation, whereas calycosin-7-O-β-D-glucopyranoside-induced osteoblast differentiation is regulated *via* the bone morphogenetic protein (BMP) and Wnt/β-catenin-signaling pathway\[[@B41]\]. The TGFβ-induced nuclear translocation of β-catenin has been reported to be one of the key factors that activates the EMT program\[[@B42]-[@B45]\]. Wnt/β-catenin is regulated in stem cells, and Wnt target genes are controlled by the TCF/β-catenin complex\[[@B46]\].

In gastrointestinal cancer, somatic mutations that provoke an immune response have been found in tumor-infiltrating lymphocytes, which may be very specific to the individual and are targets for cancer immunotherapy\[[@B47]\]. KRAS-mutation-specific T cells, as well as personalized mutation-specific T cells, have been identified, and these may be useful in the future for individual cancer immunotherapeutics\[[@B47]\]. It has been reported that *Helicobacter pylori* up-regulates Nanog and Oct4 expression *via* Wnt/β-catenin signaling\[[@B48]\]. Wnt/β-catenin signaling and the phosphorylation of β-catenin may be involved in stemness in gastric cancer\[[@B48]\].

In conclusion, CTNNB1 plays an important role in the regulation of stem cell pluripotency and cancer signaling. For future direction, precise analyses of Wnt signaling, Notch signaling, and Ephrin signaling are needed to reveal the entire picture of β-catenin signaling in cancer and stem cells. RHO mutations, and regulator of G-protein signaling, with network analysis tools, such as Cytoscape, must be investigated for a greater understanding of this process.
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